Design Therapeutics (DSGN) Other Operating Expenses (2025)

Design Therapeutics (DSGN) posted quarterly Other Operating Expenses of $59.0 million for Q4 2025, up 1166.17% on a QoQ basis from $4.7 million in Q3 2025.

Design Therapeutics (DSGN) Other Operating Expenses (2025) Analysis & Trends

Design Therapeutics has reported Other Operating Expenses for 1 years, with the latest figure at $59.0 million in Q4 2025.

  • Other Operating Expenses for Q4 2025 came in at $59.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $63.7 million (changed N/A YoY), and the FY2025 annual result was $59.0 million, changed N/A from the prior year.
  • Other Operating Expenses improved to $59.0 million in Q4 2025, from $4.7 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $59.0 million in Q4 2025 and troughed at $4.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Design Therapeutics 928.06 Mn 720.67 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 59.03 Mn
Sep 30, 2025 4.66 Mn